To Test or Re-Test, that is the Question: Comparison of the Mismatch Repair Deficiency between Primary and Recurrent Sites of Uterine Cancers (088)

医学 MSH2 MSH6型 子宫内膜癌 MLH1 子宫癌 肿瘤科 DNA错配修复 癌症 PMS2系统 内科学 原发性肿瘤 免疫组织化学 林奇综合征 病理 结直肠癌 转移
作者
Daniel Spinosa,Janice Wong,Regina S. Whitaker,Kyle C. Strickland,Rebecca A. Previs
出处
期刊:Gynecologic Oncology [Elsevier BV]
卷期号:166: S60-S60 被引量:6
标识
DOI:10.1016/s0090-8258(22)01313-0
摘要

Objectives: Mismatch repair deficiency (MMR-D) is a common genotype in uterine cancer with prognostic and therapeutic implications. Prior studies have demonstrated tumoral evolution with respect to MMR deficiency between primary and recurrent gastrointestinal cancers. Whether uterine cancers undergo similar clonal evolution between primary and recurrent sites is less well understood. The purpose of this study was to determine if MMR deficiency concordance exists between primary and recurrent disease sites in patients with uterine cancer who later develop recurrent disease. Methods: We identified patients with a history of primary and recurrent uterine cancer from a single high-volume cancer center. Histologic slides were reviewed to confirm the diagnosis of primary and recurrent cancer, and formalin-fixed paraffin-embedded tissue blocks were requested from archives. Immunohistochemistry (IHC) was performed using antibodies against mismatch repair proteins (MMR), including MLH1, PMS2, MSH2, and MSH6. Results: A total of 86 primary and recurrent matched specimens were identified from 43 patients. Eleven patients (26%) did not have sufficient tissue for analysis from the primary or recurrent site and were therefore excluded from the analysis. The majority (28/32, 88%) were at stage I at the time of diagnosis; 11/32 (34%) were high-grade epithelial, and 1/32 (3%) had carcinosarcoma. Based on IHC expression of MMR proteins, 6/32 (19%) of primary tumors had MMR deficiency (MMR-D), while 9/32 (28%) of recurrent tumors had MMR-D. All patients (6/6, 100%) with MMR-D tumors in the primary setting retained MMR-D in the recurrent setting, while 3/26 (12%) patients who were MMR proficient in the primary setting were MMR-D in the recurrent setting. Of patients with MMR-D, 5/6 (83%) were deficient due to no MLH1 and PMS2 in the primary tumor, while one tumor had no MSH2 and MSH6 expression. All six patients with MMR-D in the primary tumor had an identical IHC phenotype in the recurrent setting. Of patients whose tumor became MMR-D, 3/3 (100%) had a loss of MLH1, and 2/3 (67%) had a loss of PMS2. Two of the three patients (67%) who developed MMR-D were at grade 1 epithelial at the time of initial diagnosis. In total, 23/32 (72%) patients showed proficient expression in both the primary and recurrent tumors, and 29/32 (91%) had concordance between primary and recurrent tumors. Conclusions: Rates of MMR-D in the primary setting were 19%, consistent with rates previously reported. Patients with MMR-D uterine tumors in the primary setting are likely to remain MMR-D in the recurrent setting. We identified 12% of patients with recurrent uterine cancer who developed MMR-D in the recurrent setting. This clonal evolution represents a biomarker that has therapeutic implications for patients with recurrent uterine cancer. Objectives: Mismatch repair deficiency (MMR-D) is a common genotype in uterine cancer with prognostic and therapeutic implications. Prior studies have demonstrated tumoral evolution with respect to MMR deficiency between primary and recurrent gastrointestinal cancers. Whether uterine cancers undergo similar clonal evolution between primary and recurrent sites is less well understood. The purpose of this study was to determine if MMR deficiency concordance exists between primary and recurrent disease sites in patients with uterine cancer who later develop recurrent disease. Methods: We identified patients with a history of primary and recurrent uterine cancer from a single high-volume cancer center. Histologic slides were reviewed to confirm the diagnosis of primary and recurrent cancer, and formalin-fixed paraffin-embedded tissue blocks were requested from archives. Immunohistochemistry (IHC) was performed using antibodies against mismatch repair proteins (MMR), including MLH1, PMS2, MSH2, and MSH6. Results: A total of 86 primary and recurrent matched specimens were identified from 43 patients. Eleven patients (26%) did not have sufficient tissue for analysis from the primary or recurrent site and were therefore excluded from the analysis. The majority (28/32, 88%) were at stage I at the time of diagnosis; 11/32 (34%) were high-grade epithelial, and 1/32 (3%) had carcinosarcoma. Based on IHC expression of MMR proteins, 6/32 (19%) of primary tumors had MMR deficiency (MMR-D), while 9/32 (28%) of recurrent tumors had MMR-D. All patients (6/6, 100%) with MMR-D tumors in the primary setting retained MMR-D in the recurrent setting, while 3/26 (12%) patients who were MMR proficient in the primary setting were MMR-D in the recurrent setting. Of patients with MMR-D, 5/6 (83%) were deficient due to no MLH1 and PMS2 in the primary tumor, while one tumor had no MSH2 and MSH6 expression. All six patients with MMR-D in the primary tumor had an identical IHC phenotype in the recurrent setting. Of patients whose tumor became MMR-D, 3/3 (100%) had a loss of MLH1, and 2/3 (67%) had a loss of PMS2. Two of the three patients (67%) who developed MMR-D were at grade 1 epithelial at the time of initial diagnosis. In total, 23/32 (72%) patients showed proficient expression in both the primary and recurrent tumors, and 29/32 (91%) had concordance between primary and recurrent tumors. Conclusions: Rates of MMR-D in the primary setting were 19%, consistent with rates previously reported. Patients with MMR-D uterine tumors in the primary setting are likely to remain MMR-D in the recurrent setting. We identified 12% of patients with recurrent uterine cancer who developed MMR-D in the recurrent setting. This clonal evolution represents a biomarker that has therapeutic implications for patients with recurrent uterine cancer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
淡淡代玉完成签到,获得积分10
1秒前
半糖糖发布了新的文献求助10
1秒前
1秒前
慕青应助HelloKun采纳,获得10
2秒前
yar应助candy采纳,获得10
3秒前
hanabi完成签到,获得积分10
3秒前
李爱国应助Heartlark采纳,获得10
3秒前
3秒前
CodeCraft应助大菊采纳,获得10
4秒前
4秒前
乔哥儿发布了新的文献求助10
6秒前
王几几完成签到,获得积分10
6秒前
淡淡代玉发布了新的文献求助10
6秒前
yu发布了新的文献求助10
6秒前
6秒前
8秒前
8秒前
joseph应助半糖糖采纳,获得10
9秒前
席松发布了新的文献求助10
9秒前
乐乐应助欧欧拉格朗日采纳,获得10
9秒前
小L发布了新的文献求助10
10秒前
王几几发布了新的文献求助10
11秒前
zhouz完成签到,获得积分10
11秒前
星渊完成签到,获得积分10
13秒前
14秒前
15秒前
慢羊羊发布了新的文献求助10
15秒前
CipherSage应助yuany采纳,获得10
16秒前
Janisa完成签到,获得积分10
17秒前
cczltdy完成签到,获得积分10
18秒前
宋66发布了新的文献求助20
20秒前
hiyuz完成签到,获得积分10
20秒前
hhh完成签到 ,获得积分10
21秒前
归尘应助欧欧拉格朗日采纳,获得10
22秒前
席松完成签到,获得积分10
23秒前
卡卡西应助失忆的蝴蝶采纳,获得20
23秒前
water应助zheng能量采纳,获得10
25秒前
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969917
求助须知:如何正确求助?哪些是违规求助? 3514626
关于积分的说明 11175060
捐赠科研通 3249928
什么是DOI,文献DOI怎么找? 1795165
邀请新用户注册赠送积分活动 875617
科研通“疑难数据库(出版商)”最低求助积分说明 804891